Codiak BioSciences, Inc. (CDAK)
| Market Cap | 372.87M |
| Revenue (ttm) | 15.97M |
| Net Income (ttm) | n/a |
| Shares Out | 20.33M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $16.66 |
| Previous Close | $16.86 |
| Change ($) | -0.20 |
| Change (%) | -1.19% |
| Day's Open | 17.15 |
| Day's Range | 16.40 - 17.79 |
| Day's Volume | 106,822 |
| 52-Week Range | 7.90 - 37.85 |
– Key clinical data from first in-human studies of engineered exosome therapeutic candidates, exoIL-12™ and exoSTING™, expected this year –
– engEx™ Platform and in vitro and in vivo findings support utility across multiple therapeutic areas – – engEx™ Platform and in vitro and in vivo findings support utility across multiple therapeutic ar...
– exoSTING has demonstrated enhanced potency, preferential activation of antigen presenting cells, and systemic anti-tumor immunity in vivo –
– exoASO™-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity in multiple preclinical models; IND submission planned for H2 2021 –
– First human proof-of-concept data from exoIL-12™ program confirmed desired product profile and enabled dose selection for further evaluation in patients –
– Healthy volunteer clinical data for exoIL-12 accepted as a late-breaking abstract –
CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based ...
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based ...
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a ...
– Pharmacodynamic results confirm localized exoIL-12 pharmacologic activity
– New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties –
– exoIL-12 resulted in no local or systemic treatment-related adverse events –
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class o...
– Human clinical testing now underway with Codiak's first two candidates, exoIL-12™ and exoSTING™ –
– exoIL-12™ demonstrates tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Codiak BioSciences, Inc. (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today an...
About CDAK
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurod... [Read more...]
| Industry Biotechnology | IPO Date Oct 14, 2020 |
| CEO Douglas Williams | Employees 105 |
| Stock Exchange NASDAQ | Ticker Symbol CDAK |
Financial Performance
In 2020, CDAK's revenue was $2.92 million, an increase of 651.29% compared to the previous year's $388,000. Losses were -$91.67 million, 17.6% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for CDAK stock is "Strong Buy." The 12-month stock price forecast is 36.67, which is an increase of 120.11% from the latest price.